mRNA Synthesis and Manufacturing Market Size & Trends Report Segmented by Product (Drug Substance, Drug Product), Service Type (Synthesis, Purification, Manufacturing & Scale-up), Application (Vaccines, Therapeutics), End-user & Regional Forecast to 2030

The global mRNA synthesis and manufacturing market is expected to grow at a CAGR of ~6% during the forecast period. Growing demand for mRNA-based vaccines and therapeutics, increasing cases of infectious and chronic diseases, rapid advancements in lipid nanoparticle (LNP) delivery systems, the emergence of AI-driven platforms for mRNA design and synthesis, and the expansion of contract development and manufacturing organizations (CDMOs) are some of the key factors driving the market growth. However, stability and storage issues associated with mRNA products remain a major constraint for the growth of the mRNA synthesis and manufacturing market. To learn more about the research report, download a sample report.

Overview

The mRNA synthesis and manufacturing market represents a vital part of the biopharmaceutical industry, focused on the production of messenger RNA molecules used in vaccines and therapeutics. It involves several stages, including plasmid preparation, in vitro transcription (IVT), mRNA purification, and formulation, often utilizing lipid nanoparticles (LNPs) for effective delivery. The market includes key components such as enzymes, reagents, templates, specialized delivery systems, mRNA synthesis tools, production platforms, raw materials, analytical instruments, and fill-finish technologies that collectively enable the efficient development and large-scale manufacturing of high-quality mRNA products.

To learn more about this report, download the PDF brochure

Rising demand for mRNA-based vaccines and therapeutics drives market expansion

The global success of mRNA-based COVID-19 vaccines has generated significant interest in mRNA technology for a broad range of applications. According to an article published by the WHO in October 2024, more than 13 billion COVID-19 vaccine doses have been administered globally. The pandemic highlighted the speed, scalability, and effectiveness of mRNA platforms in responding to urgent healthcare challenges. Pharmaceutical and biotech companies are increasingly investing in mRNA-based therapeutics for infectious diseases, cancer, and rare genetic disorders. This growing demand is driving the need for high-quality raw materials, advanced synthesis platforms, and flexible, large-scale production capabilities. Additionally, the expansion of clinical trials and regulatory approvals for mRNA therapies is accelerating market growth.

Growth in personalized cancer immunotherapy drives innovation in mRNA manufacturing

The rising demand for cancer immunotherapy and personalized mRNA-based oncology vaccines presents a significant opportunity for the mRNA synthesis and manufacturing market. Unlike conventional treatments, mRNA-based cancer vaccines are tailored to target tumour-specific antigens, enhancing precision and reducing off-target effects. The personalized nature of these therapies requires rapid, flexible, and high-quality mRNA synthesis capabilities, driving demand for advanced manufacturing platforms, automation, and robust quality control systems.

Recent developments in the mRNA synthesis and manufacturing market

Recent industry developments highlight the rapid progress in mRNA synthesis and manufacturing, with advaspanning clinical trials, next-generation facilities, and innovative platforms. Companies are expanding capabilities and forging collaborations to accelerate personalized therapies, cancer vaccines, and novel delivery approaches. For instance,

• In April 2025, CureVac received the US FDA Investigational New Drug (IND) application to initiate a phase 1 clinical trial for novel mRNA-based precision immunotherapy in squamous non-small cell lung cancer
• In November 2024, SyVento Biotech, with Cytiva-s support, launched Poland-s first mRNA FlexFactory, an advanced 7,000 m facility, designed to accelerate high-quality mRNA therapy production from lab to commercial scale
• In May 2024, GenScript launched a self-amplifying RNA synthesis service for advanced therapeutic applications, boosting potency and efficiency for vaccine, immunotherapy, and gene therapy development
"aligncenter wp-image-10503 size-full" title="mRNA Synthesis and Manufacturing Market - Segmentation" src="https://meditechinsights.com/wp-content/uploads/2025/09/mRNA-Synthesis-and-Manufacturing-Market-Segmentation.png" alt="mRNA Synthesis and Manufacturing Market - Segmentation" width="922" height="612" />

To learn more about this report, download the PDF brochure

Competitive Landscape Analysis

The global mRNA synthesis and manufacturing market is marked by the presence of established and emerging market players such as Lonza Group AG; Wuxi Biologics (Cayman) Inc.; Merck KGaA; Thermo Fisher Scientific Inc.; GenScript Biotech Corporation; Sartorius AG; Takara Bio Inc.; Danaher Corporation; Promega Corporation; New England Biolabs, Inc.; and Telesis Bio Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Growth Rate

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
~6%
Market Drivers	Growing number of clinical trials targeting rare and genetic disorders Rising demand for mRNA-based vaccines and therapeutics Advancements in targeted delivery technologies such as lipid nanoparticles Increasing prevalence of chronic and infectious diseases Rising R&D investments by biotech and pharma companies
Attractive Opportunities	Integration of AI and machine learning in mRNA design Growing demand for personalized mRNA-based oncology vaccines Rising outsourcing to CDMOs for large-scale, flexible manufacturing Expansion into emerging markets
Segment Scope	Product, Service Type, Application, and End-user
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	Lonza Group AG; Wuxi Biologics (Cayman) Inc.; Merck KGaA, Darmstadt, Germany; Thermo Fisher Scientific Inc.; GenScript Biotech Corporation; Sartorius AG; Takara Bio Inc.; Danaher Corporation; Promega Corporation; New England Biolabs, Inc.; and Telesis Bio Inc.; among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global mRNA Synthesis and Manufacturing Market Segmentation

This report by Medi-Tech Insights provides thesize of the global mRNA synthesis and manufacturing market at theregional- and country-level from 2023 to 2030. The report further segments the market based on product, service type, application, and end-user.

Market Size & Forecast (2023-2030), By Product, USD Million

• Drug Substance (APIs)
• Drug Product (FDFs)
• Others

Market Size & Forecast (2023-2030), By Service Type, USD Million

• Synthesis
• Purification
• Manufacturing & Scale-up
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• mRNA-based Vaccines
• mRNA-based Therapeutics
• Oth

  Market Size & Forecast (2023-2030), By End-user, USD Million

  • Biopharma Companies
  • Academic & Research Institutes
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Others

  Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

  Key Strategic Questions Addressed

  • What is the market size & forecast of the mRNA synthesis and manufacturing market?
  • What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the mRNA synthesis and manufacturing market?
  • What are the key trends defining the market?
  • What are the major factors impacting the market?
  • What are the opportunities prevailing in the market?
  • Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
  • Who are the major players operating in the market?
  • What are the key strategies adopted by players?

  Related Reports

  Global Vaccine CDMO Market Report Segmented by Vaccine Type (mRNA, Viral Vector, Recombinant Protein, DNA Vaccine), Phase (Pre-clinical, Clinical, Commercial), End User (Biopharmaceutical & Vaccine Developers) Forecasts to 2030

  Aptamers Market Size & Forecasts, Segmentation, Dynamics, Competitive Landscape, Key Industry Trends to 2027

  Global Immuno-Oncology (IO) Market Size & Trends Report Segmented by Therapy Type (CAR-T Cell, Cancer Vaccines, Bispecific Antibodies, mAbs), Cancer Type (Lung, Breast, Colorectal, Melanoma), End User (Hospitals, Specialty Clinics) & Regional Forecast to 2030